NCT03695341View on ClinicalTrials.gov

500mg Fulvestrant Versus Everolimus Plus Exemestane in MBC Patients Refractory to Previous AI

CompletedOBSERVATIONAL
Enrollment

130

Participants

Timeline

Start Date

May 14, 2018

Primary Completion Date

March 10, 2019

Study Completion Date

May 15, 2019

Conditions
Breast Cancer
Trial Locations (1)

200032

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER

NCT03695341 - 500mg Fulvestrant Versus Everolimus Plus Exemestane in MBC Patients Refractory to Previous AI | Biotech Hunter | Biotech Hunter